Royal Cornwall Hospital

Running trials

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Recruiting

  To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting the Nature of Indeterminate Thyroid Nodules (ITNs) Across Multiple Centers.

  NCT06849284· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Source

• Recruiting

  Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)

  NCT06440174· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Source

• Recruiting

  Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

  NCT05635162· Phase 2· Source

• Active, not recruiting

  Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

  NCT05004064· Phase 2· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Source

• Active, not recruiting

  A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  NCT06097364· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Active, not recruiting

  Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

  NCT04920708· Phase 2· Source

• Recruiting

  A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

  NCT05613023· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Source

• Recruiting

  A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT05085028· Phase 3· Source

• Active, not recruiting

  Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

  NCT05201547· Phase 3· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· Source

• Active, not recruiting

  Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04546620· Phase 2· Source

• Recruiting

  Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

  NCT04774159· Phase 3· Source

• Active, not recruiting

  A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04628494· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· Source

• Active, not recruiting

  A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

  NCT03888105· Phase 2· Source

• Recruiting

  MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

  NCT04116502· Phase 3· Source

• Active, not recruiting

  Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

  NCT02804815· Phase 3· Source

• Active, not recruiting

  Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems

  NCT02314702· Source

• Active, not recruiting

  Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

  NCT02446405· Phase 3· Source

• Active, not recruiting

  Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

  NCT01761968· Phase 2· Source

• Active, not recruiting

  Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

  NCT01566240· Phase 3· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Heart failure2 recruiting
• Lung cancer2 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Multiple sclerosis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

  NCT04526899· Phase 2· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Source

• Completed

  EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  NCT03950076· Phase 4· Source

• Completed

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Terminated

  The MyoVista Angiography Angioplasty Percutaneous Coronary Intervention Trial

  NCT03635801· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Source